

Reviewer's report

Title: Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, phase II, dose-finding study

Version: 4 **Date:** 31 May 2011

Reviewer: Andrew Östör

Reviewer's report:

The authors have address the recommendations and suggestions of this reviewer adequately.

I am happy for the manuscript to be published.

Level of interest: An article of importance in its field

Quality of written English: Acceptable

Statistical review: Yes, but I do not feel adequately qualified to assess the statistics.